Who is sponsoring NCT03250923?

NCT03250923 is sponsored by CelaCare Technologies, Inc..

What condition does NCT03250923 study?

NCT03250923 studies Candidiasis, Oral.

What drugs are being tested in NCT03250923?

Interventions: silver citrate complex and acemannan.

What is the status of NCT03250923?

NCT03250923 is currently UNKNOWN.

Last reviewed 2024-02-08 · How we verify

CelAgace™ OraRinse (CAOR) Pilot Clinical Study for Management of Candidiasis Associated With Grade 0-II Mucositis

NCT03250923 Phase 1/Phase 2 UNKNOWN

CelAgace™ OraRinse (silver citrate complex and acemannan) Solution is planned to be evaluated for safety and effectiveness as a potential treatment for candidiasis, a yeast infection, commonly known as thrush, which is associated with mouth sores.

Details

Lead sponsor	CelaCare Technologies, Inc.
Phase	Phase 1/Phase 2
Status	UNKNOWN
Enrolment	15
Start date	2024-09
Completion	2025-05

Conditions

Candidiasis, Oral

Interventions

silver citrate complex and acemannan

Primary outcomes

Clinical cure as demonstrated by change and reduction from baseline in typical candida lesions and a negative candida rinse culture — Days 1(Baseline), 3, 7 and 14
Rinse culture will be taken on Days 1, 7 and 14 to quantify Candidal Colony Forming Units and observational assessment will be done at study entry, Day 1, Days 3, 7, 14 using the WHO grading scale for response evaluation.

Countries

United States